Longeveron Inc (NQ: LGVN )
2.200
-0.250
(-10.20%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 21, 2024
Add to My Watchlist
All News about Longeveron Inc
![](https://investorplace.com/wp-content/uploads/2022/01/insider-buying.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_379.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/mid-day_movers_image_104.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_376.png)
![](https://investorplace.com/wp-content/uploads/2019/07/wall-street-man-on-laptop.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/premkt_movers_537.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_366.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/mid-day_movers_image_94.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/untitled_design_26_0.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/lab-gf3ce8b789_1280.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/dementia-3051832_1920_6.jpg)
Alzheimer’s Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases
January 05, 2022
Topics
Death
Exposures
Death
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/mid-day_movers_image_87.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_357.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/mid-day_movers_image_85.jpg)
Systemic Mastocytosis Treatments Gain Hope Due To Increasing Novel Treatment Options
December 21, 2021
Exposures
Product Safety
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/dices-over-newspaper-2656028_1920_88.jpg?width=720)
![](https://investorplace.com/wp-content/uploads/2020/05/short-squeeze1600.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/squeeze.jpg)
![](https://investorplace.com/wp-content/uploads/2021/12/weather-1600-1024x576.png)
![](https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715.png)
Why Longeveron’s Good News Isn’t Telling Us the Whole Truth
December 10, 2021
Via InvestorPlace
Topics
Initial Public Offering
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/premkt_movers_509.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/mid-morning-market-update_84.jpg)
Mid-Morning Market Update: Markets Open Lower; US Initial Jobless Claims Drop To 52-Year Low
December 09, 2021
Via Benzinga
Topics
Stocks
Exposures
US Equities
![](https://investorplace.com/wp-content/uploads/2020/07/pharma-stocks.jpg)
![](https://investorplace.com/wp-content/uploads/2019/07/biotech1600gene.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_343.png)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.